[144] Beta Bionics, Inc. SEC Filing

Rhea-AI Filing Summary

Form 144 notice from Beta Bionics, Inc. (BBNX) records a proposed sale of 5,587 common shares through Merrill Lynch on the NASDAQ with an aggregate market value of $95,171.78, listed for sale on 08/19/2025. The shares were acquired by stock option from Beta Bionics with payment in cash on the same date. The filing also discloses a prior sale by Stephen Feider of 1,497 shares on 06/02/2025 for $26,783.06. By signing, the seller represents no undisclosed material adverse information exists and acknowledges potential criminal penalties for false statements.

Positive

• Planned sale fully disclosed: 5,587 common shares through Merrill Lynch on NASDAQ scheduled 08/19/2025 with aggregate market value of $95,171.78.
• Acquisition and payment details provided: Shares were acquired via stock options from Beta Bionics and paid in cash on 08/19/2025, clarifying the transaction basis.
• Compliance representation included: Seller attests no undisclosed material adverse information and acknowledges legal penalties for false statements.

Negative

• Insider sale activity: A prior sale of 1,497 shares by Stephen Feider on 06/02/2025 for $26,783.06 is disclosed, indicating recent insider liquidity.
• Limited context on materiality: Filing contains transactional facts but does not state whether sales are part of a trading plan or linked to company events.

Insights

Securities Analyst

TL;DR: An insider exercise and planned sale of 5,587 shares is disclosed; amounts are modest and indicate routine liquidity rather than major corporate change.

The Form 144 shows a securities sale planned through Merrill Lynch on NASDAQ for 5,587 common shares with an aggregate market value of $95,171.78, resulting from stock options exercised on 08/19/2025 and paid in cash the same day. The filing complies with Rule 144 notice requirements and provides transparency on insider liquidity. A prior sale of 1,497 shares on 06/02/2025 for $26,783.06 by Stephen Feider is also disclosed. Given the absolute dollar amounts shown, this filing appears to reflect personal liquidity events rather than material capital market activity for the issuer.

Corporate Governance Expert

TL;DR: The filer followed regulatory disclosure protocols; the representation about absence of material nonpublic information is standard and important for compliance.

The document includes the required representation that the seller does not possess undisclosed material adverse information and notes the potential criminal penalties for false statements, aligning with compliance norms. The securities were acquired via stock options from the issuer and will be sold through a broker on a public exchange, which supports orderly disclosure of insider transactions. No additional governance actions, trading plan dates, or indications of Rule 10b5-1 reliance are provided in the filing.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Merrill Lynch 6002 El Tordo 2nd FL PO BOX 7297 Rancho Santa Fe CA 92067	5587	95171.78	43470125	08/19/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	08/19/2025	Stock Options	Beta Bionics			5587	08/19/2025	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Stephen Feider 11 HUGHES Irvine CA 92618	Common	06/02/2025	1497	26783.06

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What shares does the Form 144 for Beta Bionics (BBNX) report for sale?

The filing reports a proposed sale of 5,587 common shares through Merrill Lynch on NASDAQ.

What is the aggregate market value and scheduled sale date for the reported BBNX sale?

The aggregate market value is $95,171.78 and the approximate date of sale is 08/19/2025.

How were the 5,587 shares acquired according to the filing?

The shares were acquired on 08/19/2025 via stock options from Beta Bionics and paid in cash on that date.

Does the filing disclose any recent sales by related persons?

Yes. The filing discloses a sale by Stephen Feider of 1,497 shares on 06/02/2025 for $26,783.06.

Does the Form 144 state reliance on a Rule 10b5-1 trading plan?

No. The filing does not provide a date of plan adoption or indicate reliance on a Rule 10b5-1 trading plan.